Deep Brain Stimulation (DBS) for the Treatment of Parkinson’s Disease (INTREPID)

LOCATION: Englewood Colorado 

TRIAL STATUS: Open for Enrollment 


This study investigates the use of a new DBS device, Boston Scientific Corporation Vercise™ deep brain stimulation system for Parkinson’s disease. This study measures changes in motor symptoms, on time and quality of life.

Who is considered for the INTREPID DBS study?

  • Individuals with a diagnosis of Parkinson’s disease for at least 5 years with symptoms on both sides of the body and disabling symptoms despite optimal medical therapy.
  • Must be able to understand the study requirements and undergo the evaluation, treatment and follow-up procedures.
  • Age of 22 to 75 years.


People that have any of the following is not considered for the INTREPID DBS study: 

  • A brain or medical condition that would prohibit DBS surgery.
  • A significant or untreated condition affecting mood or thinking skills.
  • Other implanted devices including neurostimulators and /or medication pump.
  • Anyone with previous thalamotomy, pallidotomy or prior DBS procedure.
  • A significant medical condition that may interfere with treatment or procedures.
  • Women who are breastfeeding or not taking a pregnancy prevention therapy.


Contact Information: Principle Investigator Dr. Monique Giroux

Phone: 303-781-0511 during hours from 8 a.m. to 4 p.m. Mountain time, Monday through Friday